SG Americas Securities LLC decreased its stake in shares of Ardelyx, Inc. (NASDAQ:ARDX) by 36.9% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 11,126 shares of the biopharmaceutical company’s stock after selling 6,497 shares during the period. SG Americas Securities LLC’s holdings in Ardelyx were worth $141,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of ARDX. Parametric Portfolio Associates LLC acquired a new position in Ardelyx during the first quarter valued at $320,000. Bank of New York Mellon Corp boosted its position in shares of Ardelyx by 4.8% in the first quarter. Bank of New York Mellon Corp now owns 145,916 shares of the biopharmaceutical company’s stock valued at $1,846,000 after buying an additional 6,647 shares during the last quarter. Teachers Advisors LLC boosted its position in shares of Ardelyx by 45.1% in the fourth quarter. Teachers Advisors LLC now owns 47,230 shares of the biopharmaceutical company’s stock valued at $671,000 after buying an additional 14,690 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in shares of Ardelyx by 11.7% in the fourth quarter. Metropolitan Life Insurance Co. NY now owns 22,824 shares of the biopharmaceutical company’s stock valued at $324,000 after buying an additional 2,382 shares during the last quarter. Finally, Renaissance Technologies LLC boosted its position in shares of Ardelyx by 41.1% in the fourth quarter. Renaissance Technologies LLC now owns 66,300 shares of the biopharmaceutical company’s stock valued at $941,000 after buying an additional 19,300 shares during the last quarter. Institutional investors own 82.47% of the company’s stock.

Shares of Ardelyx, Inc. (ARDX) traded down 5.21% during midday trading on Monday, hitting $4.55. 354,209 shares of the stock traded hands. Ardelyx, Inc. has a 12-month low of $4.05 and a 12-month high of $16.30. The company’s market capitalization is $215.61 million. The firm’s 50 day moving average price is $5.25 and its 200 day moving average price is $9.78.

Ardelyx (NASDAQ:ARDX) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($0.59) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.06. Analysts expect that Ardelyx, Inc. will post ($2.46) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/08/07/ardelyx-inc-nasdaqardx-shares-sold-by-sg-americas-securities-llc-updated-updated-updated.html.

Several brokerages have commented on ARDX. ValuEngine cut shares of Ardelyx from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd. Cantor Fitzgerald reissued a “buy” rating and issued a $12.00 price target on shares of Ardelyx in a research report on Wednesday, May 31st. Zacks Investment Research lowered shares of Ardelyx from a “buy” rating to a “hold” rating in a research report on Tuesday, July 18th. BTIG Research reduced their price target on shares of Ardelyx from $18.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday, May 23rd. Finally, BidaskClub raised shares of Ardelyx from a “sell” rating to a “hold” rating in a research report on Wednesday, July 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $14.13.

Ardelyx Company Profile

Ardelyx, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutics focuses on addressing cardiorenal and gastrointestinal (GI) diseases. It operates through the research, development and commercialization of biopharmaceutical products segment. The Company’s products line includes cardiorenal portfolio and gastrointestinal portfolio.

Institutional Ownership by Quarter for Ardelyx (NASDAQ:ARDX)

Receive News & Stock Ratings for Ardelyx Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ardelyx Inc. and related stocks with our FREE daily email newsletter.